Clinical Trial Update: Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral Neuropathy [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating N0750 compared with monotherapies for Painful Diabetic Peripheral Neuropathy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Painful Diabetic Peripheral Neuropathy

Drugs mentioned

• N0750

Snippet

Sponsor: Eurofarma Laboratorios S.A. | Conditions: Painful Diabetic Peripheral Neuropathy (PDPN) | Phase 3 | Status: WITHDRAWN